Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Myeloproliferative Disorders 1Leukemia, Biphenotypic, Acute 1Ganglioneuroblastoma 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Magnetic Resonance Spectroscopy 5Cyclophosphamide 5dinutuximab 3Topotecan 3Etoposide 3Doxorubicin 3Carboplatin 3Biopsy 3sargramostim 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Colony-Stimulating Factors 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2iberdomide 1gallium Ga 68 dotatate 1fludarabine 1Watchful Waiting 1Transurethral Resection of Bladder 1Temozolomide 1Razoxane 1Radiotherapy 1Proton Therapy 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × Razoxane × 90 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡